456 related articles for article (PubMed ID: 32964440)
21. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
Front Immunol; 2022; 13():773264. PubMed ID: 35185876
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive profiling identifies a novel signature with robust predictive value and reveals the potential drug resistance mechanism in glioma.
Zeng F; Wang K; Liu X; Zhao Z
Cell Commun Signal; 2020 Jan; 18(1):2. PubMed ID: 31907037
[TBL] [Abstract][Full Text] [Related]
23. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
24. A 4-gene panel predicting the survival of patients with glioblastoma.
Guo XX; Su J; He XF
J Cell Biochem; 2019 Sep; 120(9):16037-16043. PubMed ID: 31081973
[TBL] [Abstract][Full Text] [Related]
25. Prospective Series of Nine Long Noncoding RNAs Associated with Survival of Patients with Glioblastoma.
Lei B; Yu L; Jung TA; Deng Y; Xiang W; Liu Y; Qi S
J Neurol Surg A Cent Eur Neurosurg; 2018 Nov; 79(6):471-478. PubMed ID: 29959764
[TBL] [Abstract][Full Text] [Related]
26. Proteomics-based prognostic signature and nomogram construction of hypoxia microenvironment on deteriorating glioblastoma (GBM) pathogenesis.
Wen YD; Zhu XS; Li DJ; Zhao Q; Cheng Q; Peng Y
Sci Rep; 2021 Aug; 11(1):17170. PubMed ID: 34446747
[TBL] [Abstract][Full Text] [Related]
27. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
28. Integrated microenvironment-associated genomic profiles identify LRRC15 mediating recurrent glioblastoma-associated macrophages infiltration.
Tang H; Liu W; Xu Z; Zhao J; Wang W; Yu Z; Wei M
J Cell Mol Med; 2021 Jun; 25(12):5534-5546. PubMed ID: 33960636
[TBL] [Abstract][Full Text] [Related]
29. Characterization of ferroptosis signature to evaluate the predict prognosis and immunotherapy in glioblastoma.
Zhu X; Zhou Y; Ou Y; Cheng Z; Han D; Chu Z; Pan S
Aging (Albany NY); 2021 Jul; 13(13):17655-17672. PubMed ID: 34244461
[TBL] [Abstract][Full Text] [Related]
30. Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma.
He X; Zhang S; Chen J; Li D
Cancer Med; 2019 May; 8(5):2031-2040. PubMed ID: 30848102
[TBL] [Abstract][Full Text] [Related]
31. Six-Transmembrane Epithelial Antigen of Prostate 3 Predicts Poor Prognosis and Promotes Glioblastoma Growth and Invasion.
Han M; Xu R; Wang S; Yang N; Ni S; Zhang Q; Xu Y; Zhang X; Zhang C; Wei Y; Ji J; Huang B; Zhang D; Chen A; Li W; Bjerkvig R; Li X; Wang J
Neoplasia; 2018 Jun; 20(6):543-554. PubMed ID: 29730475
[TBL] [Abstract][Full Text] [Related]
32. A novel methylation signature predicts radiotherapy sensitivity in glioma.
Feng Y; Li G; Shi Z; Yan X; Wang Z; Jiang H; Chen Y; Li R; Zhai Y; Chang Y; Zhang W; Yuan F
Sci Rep; 2020 Nov; 10(1):20406. PubMed ID: 33230136
[TBL] [Abstract][Full Text] [Related]
33. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
34. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
[TBL] [Abstract][Full Text] [Related]
35. High expression of RFX4 is associated with tumor progression and poor prognosis in patients with glioblastoma.
Jeong HY; Kim HJ; Kim CE; Lee S; Choi MC; Kim SH
Int J Neurosci; 2021 Jan; 131(1):7-14. PubMed ID: 32075484
[No Abstract] [Full Text] [Related]
36. Predictive potential of STEAP family for survival, immune microenvironment and therapy response in glioma.
Zhao Z; Wang Z; Song Z; Wu Y; Jin Q; Zhao Z
Int Immunopharmacol; 2021 Dec; 101(Pt A):108183. PubMed ID: 34649092
[TBL] [Abstract][Full Text] [Related]
37. A risk signature with four autophagy-related genes for predicting survival of glioblastoma multiforme.
Wang Y; Zhao W; Xiao Z; Guan G; Liu X; Zhuang M
J Cell Mol Med; 2020 Apr; 24(7):3807-3821. PubMed ID: 32065482
[TBL] [Abstract][Full Text] [Related]
38. Establishment of an Immune-Related Gene Signature for Risk Stratification for Patients with Glioma.
He J; Zeng C; Long Y
Comput Math Methods Med; 2021; 2021():2191709. PubMed ID: 34497663
[TBL] [Abstract][Full Text] [Related]
39. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
40. Integrated Transcriptomic Analysis of Necrosis-related Gene in Diffuse Gliomas.
Wang J; Ma J
J Neurol Surg A Cent Eur Neurosurg; 2019 Jul; 80(4):240-249. PubMed ID: 30934097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
